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BACKGROUND. Melanoma accounts for  79% of skin cancer-related deaths, al-
though it accounts for only 4% of skin cancer incidence. Given the potential for
lethality, it is likely that patients with melanoma may experience significant emo-
tional distress. The current study was designed to determine the effect of a
cognitive-behavioral intervention on distress and health-related quality of life
(HRQOL) in patients with melanoma who had medium-to-high distress.
METHODS. Forty-eight patients who had Global Severity Index scores  60 2
months after their initial visit to the multidisciplinary melanoma clinic were
randomized to receive either standard care or 4 sessions of a cognitive-behavioral
intervention (CBI). Repeated assessments using the Brief Symptom Inventory, the
Medical Outcomes Survey Short Form-36, and the State-Trait Anxiety Inventory
occurred at baseline, at 2 months, and at 6 months after intervention for both
groups.
RESULTS. An intent-to-treat analysis did not reveal significantly lower distress in
the CBI group at 2 months or 6 months of follow-up, although differences were
noted in anxiety and HRQOL. An effect-of-intervention analysis did reveal lower
levels of distress in the CBI group at 2 months, with differences approaching
significance at 6 months.
CONCLUSIONS. The four-session CBI significantly reduced distress and improved
HRQOL for a period of 2 months in patients with melanoma who had medium-
to-high distress, with improved general health evident 6 months after the inter-
vention. Some variation in results was revealed in an intent-to-treat analysis. The
initial evidence from the current study showed that a brief intervention may be
effective for creating change in individuals with cancer who have increased dis-
tress, although further research is needed to identify the most optimal approach for
delivering the intervention. Cancer 2003;98:854 – 64.
© 2003 American Cancer Society.
KEYWORDS: intent-to-treat analysis, melanoma, distress, cognitive-behavioral in-
terventions.
Melanoma is the seventh most common cancer in the UnitedStates and is the fifth most common cancer in men. It also is the
second most common cancer in women ages 30 –35 years and the
most common cancer in women ages 25–29 years.1,2 The incidence of
melanoma is greater in men compared with women,2,3 with  25% of
melanomas occurring in individuals younger than age 45 years. Since
1973, the incidence rate per year per 100,000 population has more
than doubled from 6.8 per 100,000 population to 17.4 per 100,000
population.3 Although it accounts for only 4% of diagnoses of skin
cancer, melanoma accounts for  79% of skin cancer–related deaths.
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Current projections indicate that approximately
53,600 Americans are expected to be diagnosed with
melanoma in the year 2002.4 The rising incidence rate
for melanoma is of concern, because it is a particularly
deadly form of skin cancer if it is allowed to advance.
In particular, 5-year survival rates are  90% in pa-
tients with melanoma classified as Stage I (tumor
thickness  1.0 mm or tumor thickness 1.01–2.0 mm
without ulceration).5 Similar to with other types of
cancers, survival decreases dramatically as the tumor
advances, with 5-year survival rates in patients with
Stage IV melanoma (distant metastases) approaching
10%. Given the rapidly increasing incidence and po-
tential for lethality of this disease, it would not be
surprising to find that distress is as prevalent in these
patients as it is in patients with other types of malig-
nant disease.
Indeed, in a previous report,6 we identified signif-
icant levels of emotional distress (i.e., increased levels
of anxiety, depression, and adjustment disorders) in
approximately 30% of patients melanoma, a level that
matches the level of distress identified in more general
samples of patients with cancer.7,8 Distress has been
associated with decreased quality of life (QOL), in-
creased recurrence and mortality rates, increased
costs and utilization of resources, and decreased ad-
herence to treatment, including chemotherapy.9 –11
Early identification of distress and institution of effec-
tive treatment to relieve it may provide benefits to
patients, providers, and the health care systems in
which they participate. One way that it may provide
benefits to patients is through improved QOL. QOL
has been an important research outcome measure in
patients with cancer for the past 15 years, although it
rarely is assessed or included as an objective in clinical
oncology research trials.12 Although it is somewhat
difficult to define, Cella and Bonomi13 have identified
health-related QOL as the degree to which a medical
diagnosis or treatment for a patient with such a diag-
nosis affects an individual’s physical, social, and emo-
tional well-being. Several measures have been devel-
oped to assess the impact of medical illness on well
being, including the Medical Outcomes Survey-Short
Form-36 (SF-36).
The vast majority of research into cancer-related
QOL has focused on patients with either breast carci-
noma or prostate carcinoma. In these populations,
QOL has been related significantly to distress and
symptom presence (e.g., fatigue, pain, nausea).14,15
Few studies, however, have researched the QOL of
patients with melanoma. An exception is a recent
study by Brown et al.,16 who examined the course of
QOL in patients with late-stage melanoma (Stage IV)
every 3 months for up to 2 years and found consider-
able variability between patients. Despite this finding,
on average, a reduction in physical well-being was
noted, which was not surprising given the poor prog-
nosis for these patients. To our knowledge, this is the
only study documenting the course of QOL in patients
with melanoma. Thus, QOL has not been examined in
patients with earlier stage melanoma, and no studies
have focused on testing an intervention designed to
improve the QOL of patients with melanoma.
Currently, significant numbers of studies have
been designed to treat distress in patients with cancer
(for reviews, see Trijsburg et al.17 and Andersen18).
Interventions have ranged from individuals to groups,
have included educational as well as therapeutic in-
formation, and have been delivered in several differ-
ent modalities with positive outcomes.18 Studies sug-
gest that regardless of the method of delivery (e.g.,
face-to-face, telephone), the most effective interven-
tions for treating emotional distress focus on provid-
ing education, behavioral training, stress manage-
ment, cognitive therapy, and support.19 –22 Previous
results from group intervention studies for reducing
distress in patients with melanoma have reported pos-
itive improvements in distress, coping, and survival.9
Many of these interventions, however, are less struc-
tured and longer-term; as such, they may not fit easily
into existing medical systems. Few brief, replicable
therapeutic interventions aimed at decreasing distress
and improving QOL for specific subpopulations of
patients with cancer have been tested. Thus, the cur-
rent study was designed to determine the effect of a
brief, manualized, cognitive-behavioral intervention
(CBI) compared with standard medical care on dis-
tress and QOL in patients with medium and high
distress. It was hypothesized that patients who re-
ceived the intervention would report significantly
lower levels of distress and improved QOL compared
with preintervention scores and compared with a
group of patients who received standard medical care.
MATERIALS AND METHODS
Patients
This study was part of a larger study of distress in
patients with melanoma conducted in the Multidisci-
plinary Melanoma Clinic (MMC) at the University of
Michigan’s Comprehensive Cancer Center.6 Partici-
pants for the study were recruited after approval of the
study was obtained from the University of Michigan’s
Institutional Review Board. In the larger study, pa-
tients were referred to the MMC by primary care phy-
sicians, dermatologists, internists, and surgeons; and
they were eligible for participation if they were older
than age 18 years, able to read and understand En-
glish, and able to give their own consent, and if they
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did not have a history of chemical dependency, inpa-
tient psychiatric treatment, head injury with loss of
consciousness, or Stage IV melanoma. Three hundred
seventy-five patients met the inclusion criteria and
provided information from their initial visit to the
MMC.
An additional criterion for this part of the study
was a 2-month assessment Brief Symptom Inventory
(BSI) Global Severity Index (GSI) score  60. Of 247
patients who completed the 2-month assessment, 52
patients met this criterion. The average age of partic-
ipants was 53.4 years (standard deviation [SD], 15.36
years; range, 22–92 years). Thirty-eight patients (73%)
were married, with the remaining 14 patients (27%)
divorced, separated, widowed, or never married. The
sample was highly educated, with 69% of patients
having completed at least 1 year of college (mean
 SD, 4.86  2.72 years of college). Sixteen patients
were male. Twenty-nine patients (50%) were working,
15 patients (29%) were retired, and the remaining 8
patients (15%) were not working. Patients had their
disease staged according to the American Joint Com-
mittee on Cancer (AJCC) criteria; 26% of patients had
Stage 0 disease, 44% of patients had Stage I disease,
22% of patients had Stage II disease, and 8% of patient
had Stage III disease.
Procedure
Participants completed the BSI, the SF-36, and the
State-Trait Anxiety Inventory (STAI) at their initial pre-
sentation to the MMC and again 2 months later after
they underwent any initial surgical procedure. For the
purposes of the current study, this second assessment
served, and is referred to, as the baseline assessment
(t0). Participants who met the aforementioned criteria
at this assessment were assigned randomly to receive
either standard medical treatment or standard medi-
cal treatment plus CBI.
Individuals who were assigned randomly to the
CBI treatment group received a psychiatric intake and
3 subsequent 50-minute weekly sessions focused on
relaxation training, cognitive challenging, and prob-
lem solving. Each session was devoted to a discussion
of one of the topics, with the content tailored to spe-
cific patient examples. Patients attended sessions
once per week over a period of 4 weeks. The average
interval between the baseline assessment (t0) and the
second assessment (t2) assessment was 3.31 months
(SD, 0.73 months). Two months (t2) and 6 months (t6)
after the last psychotherapy session, individuals in the
interventional and control groups were sent addi-
tional questionnaire packages to complete.
Measures
BSI
The BSI is a 53-item measure of emotional distress
that takes 5–10 minutes to complete.23,24 It is the short
version of the revised Symptom Check List and has
well-demonstrated reliability and validity.25 Individual
items are answered on a 0 – 4 scale (0  not at all
distressed; 4  extremely distressed) and are summed
into 1 of 9 clinical scales and 3 summary scales. Spe-
cific test-retest reliability over a 2-week interval ranges
from 0.68 for the Somatization scale to 0.91 for Phobic
Anxiety. The GSI, which provides the most sensitive
measure of overall distress, has a stability coefficient
of 0.90. Thus, the BSI, and the GSI scale in particular,
have excellent ability to consistently measure distress
over time.23,24 The BSI is standardized using area T-
scores, each with a mean of 50 and an SD of 10. In
other studies with patients who had cancer, the GSI
scale of the BSI was sensitive for detecting changes
after psychologic interventions.22
SF-36
The SF-36 is a 36-item questionnaire that assesses
health functioning.26 It is composed of eight scales
that include physical functioning, social functioning,
bodily pain, and mental health. It has demonstrated
reliability and validity. In particular, 2-week and
6-month test-retest reliability for the scales ranges
from 0.43 to 0.90, and the majority of scales have
reliability scores  0.60, demonstrating their use as a
measure of health over time.26 The SF-36 was chosen
over several more specific measures of QOL (e.g., the
Functional Assessment of Cancer Treatment or the
Functional Living Index for Cancer) because of the
desire to obtain a measure of initial health functioning
when individuals may be unaware of their diagnosis of
cancer. Because the SF-36 does not specifically men-
tion cancer, individuals are not likely to become more
distressed by completing the questionnaire. It was
used in the current study as a general measure of QOL.
STAI
The STAI is a 40-item questionnaire that was designed
to assess transient or situational and stable or dispo-
sitional symptoms of anxiety.27,28 The questionnaire
consists of 2 series of 20 statements that have been
used to describe individuals (e.g., I feel nervous and
restless). Participants are asked to respond to the first
20 statements (assessing state anxiety) according to
how well each describes them at the moment they
complete the questionnaires and to the second 20
statements (assessing trait anxiety) according to how
they generally feel. Responses are rated from 1 (not at
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all/almost never) to 4 (very much so/almost always).
Scores are summed and divided by 20 to provide av-
erage state and trait anxiety scores. Test-retest stabil-
ity coefficients are reasonably high for the trait scale
and low for the state scale, as expected given the two
aspects of anxiety measured.28 The STAI was chosen to
provide an additional measure of anxiety and because
of its ability to differentiate between situational and
more characteristic manifestations of anxiety.
Statistical Analyses
The a priori primary objectives of the current study
were as follows: first, to identify levels of distress,
health functioning, and coping styles of individuals
upon initial presentation for the treatment of mela-
noma at a large tertiary-care clinic; and, second, to
identify patients who were experiencing high emo-
tional distress after undergoing surgical treatment for
melanoma and to determine the influence of provid-
ing a CBI, compared with standard medical care, on
emotional distress. Secondary objectives included 1)
reporting the differences in subjective QOL scores (SF-
36) between patients who received the CBI and pa-
tients who received standard medical care and 2) de-
scribing the longitudinal course of distress and health
functioning. For the first primary objective, a cross-
sectional description of the level of distress, QOL, and
coping skills of patients with melanoma have been
published previously.6 The current report includes the
results of the latter primary and secondary objectives.
The study was designed specifically to identify at least
50 patients who reported moderate distress (GSI  60)
at their postsurgical follow-up visit and to randomized
those patients evenly to receive either the CBI or stan-
dard medical care.
Historical information from a previously con-
ducted study that examined pretherapeutic and post-
therapeutic interventions for emotional distress, as
measured by the GSI of the BSI, was used to estimate
the mean and variability of GSI scores for this trial.
Specifically, the mean GSI score at baseline was esti-
mated at approximately 64.0, with an SD of 8.2 and a
correlation between preintervention and postinter-
vention scores of 0.6. Assuming constant variance over
time, it was estimated that with 50 patients random-
ized evenly to receive either intervention or observa-
tion, the trial would have at least 90% power to detect
a difference in distress of at least 10 points between
groups. Twenty-five patients per group was the cho-
sen sample size to allow for high power for the group
comparison, even if the drop-out rate approached
20% for the trial as a whole.
Patients were randomized to receive usual care or
CBI in a one-to-one fashion using a blinded, block-
randomization scheme. Although they agreed to the
conditions of randomization, several participants who
were randomized to receive the CBI either were un-
able to attend or chose not to attend sessions. Conse-
quently, three groups emerged: Patients who were
randomized to received and received the intervention,
patients who were randomized to receive and chose
not to receive the intervention, and patients who were
randomized to receive standard medical care. Given
these groups, two separate analytic strategies were
employed: one based on randomization, an intent-to-
treat (ITT) analysis, and the other based on whether
the patient received the CBI, an effect-of-intervention
(EOI) analysis. Baseline demographic features for the
patients were compared by randomization (ITT) or by
intervention status (EOI) using the Fisher exact test for
characteristics that were categoric in nature and the
two-sample t test for continuously distributed charac-
teristics. Not all patients responded to questionnaires
at each time point (sample sizes for each group at each
survey time point are listed in Tables 1 and 2); there-
fore, longitudinal changes in distress, as measured by
the GSI, other BSI subscales, and the subscales of the
SF-36, were compared over time using mixed-effects,
repeated-measures models.29 The mixed-effects
model allowed the modeling of all available survey
information at each time point, with the implicit as-
sumption that missingness is an ignorable random
process, often called missing at random. Each pa-
tient’s longitudinal time course for the outcome of
interest (e.g., GSI, SF-36 subscale, etc.) was modeled
allowing for random deviations from the group mean
at baseline (intercept) and over time (slope). It was
assumed that correlations within a category over time
followed an unstructured form, rather than an autore-
gressive form, because the latter may be influenced
unduly by missing data.29 Randomization assignment
and intervention status were modeled as fixed effects.
Fixed-effect group means were modeled as a function
of time and time squared to allow for curvature in the
average profile over time.30,31 Estimated group means
were compared using appropriate contrasts with the
calculation of the F-statistic at each survey point. F-
statistics, given the numerator and denominator de-
grees of freedom, with P values less than the standard,
acceptable type I error rate of 5% were considered
significantly different.
RESULTS
Fifty-two patients met the criteria for medium-to-high
distress (GSI score  60) at postsurgical follow-up,
although 4 patients declined further participation and
were not randomized to intervention conditions.
Therefore, for the ITT analysis, 25 individuals were
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randomized to the intervention, and 23 patients were
randomized to standard care. The characteristics of
the ITT groups are given in Table 1. It is noteworthy
that the patient groups were similar with regard to
gender, race (all Caucasian), age, years of education,
marital status, employment history, and stage of mel-
anoma (1997 AJCC staging system). Loss to follow-up
over successive survey time points was noted for all
groups. At the last survey time point (the 6-month
follow-up), information was obtained from 18 of 25
patients (72%) in the intervention group and 16 of 23
patients (70%) in the standard care group.
In the EOI analysis, patients who chose not to
attend the intervention were combined with individ-
uals who were randomized to receive standard care,
resulting in an intervention group (n  15 patients)
and a nonintervention group (n  33 patients). The
characteristics of the EOI groups are given in Table 2.
Like the ITT analysis, the groups were similar with
regard to gender, race (all Caucasian), age, years of
education, marital status, employment history, and
stage of melanoma (1997 AJCC staging system). Loss
to follow-up over successive survey time points was
noted for all groups. At the last survey time point (the
6-month follow-up), information was obtained from
13 of 15 patients (87%) who received the intervention
and 21 of 33 patients (64%) who did not receive the
intervention.
ITT Analyses
At the time of randomization (t0), groups had similar
overall QOL, as measured by the SF-36 scales and the
STAI Trait scale. In particular, groups were similar on
the Physical Functioning, Bodily Pain, General Health,
Social Functioning, and Mental Health scales of the
SF-36. Table 3 reports the estimated mean scores for
each scale at each time point from longitudinal mixed-
effects models.
TABLE 1








Two months 21 18
Six months 18 16
Male gender
No. 8 6











Never married 1 (4.0) 2 (8.7)
Married 17 (68.0) 17 (73.9)
Divorced 5 (20.0) 1 (4.4)
Separated 0 (0.0) 1 (4.4)
Widowed 2 (8.0) 2 (8.7)
Employment (%)
Currently working 13 (52.0) 13 (56.5)
Worked in past 6 months 2 (8.0) 1 (4.4)
Retired 8 (32.0) 7 (30.4)
Not working  6 months 2 (8.0) 2 (8.7)
Disease stage (AJCC 1997) (%)
Stage 0 5 (20.0) 8 (34.8)
Stage I 14 (56.0) 7 (30.4)
Stage II 6 (24.0) 4 (17.4)
Stage III 0 (0.0) 4 (17.4)
a AJCC: American Joint Committee on Cancer.
TABLE 2








Two months 14 25
Six months 13 21
Male gender
No. 4 10











Never married 0 (0.0) 3 (9.71)
Married 13 (86.7) 21 (63.6)
Divorced 2 (13.3) 4 (12.1)
Separated 0 (0.0) 1 (3.0)
Widowed 0 (0.0) 4 (12.1)
Employment (%)
Currently working 7 (46.7) 19 (57.6)
Worked in past 6 months 2 (13.3) 1 (3.0)
Retired 4 (26.7) 11 (33.3)
Not working  6 months 2 (13.3) 2 (6.1)
Disease stage (AJCC 1997) (%)
Stage 0 4 (26.7) 9 (27.3)
Stage I 9 (60.0) 12 (36.4)
Stage II 2 (13.3) 8 (24.2)
Stage III 0 (0.0) 4 (12.1)
a AJCC: American Joint Committee on Cancer.
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Contrary to our hypothesis, distress, as measured
by the GSI of the BSI, was not impacted significantly
by intervention, although anxiety, as measured by the
STAI State scale and the Anxiety scale of the BSI, were
significantly lower for the intervention group at
2-month follow-up and 6-month follow-up, respec-
tively. Table 4 presents the mean scores with standard
errors and the significant differences between the two
groups at each time point. Thus, although overall dis-
tress was not affected significantly by the intervention,
significant reductions in anxiety were observed both
immediately after the intervention and a short interval
after the intervention.
Although the intervention was constructed to help
patients reduce their level of distress, it also appears to
have increased significantly several aspects of health
functioning. In particular, General Health, Vitality, So-
cial Functioning, and Mental Health scores of the
SF-36 all improved immediately after treatment. When
comparing patients who received the intervention
with patients who received standard care, at the
2-month follow-up, General Health scores were 17.1
points higher (P  0.008), Vitality scores were 13.5
points higher (P  0.04), Social Functioning scores
were 15.8 points higher (P  0.04), and Mental Health
scores were 15.6 points higher (P  0.01) for the in-
tervention group. Unfortunately, these differences
were not observed at the 6-month follow-up, with the
exception of General Health scores, which remained
12.4 points higher (P  0.05) for the intervention
group.
EOI Analyses
Like the ITT analyses, at the time of randomization
(t0), groups had similar overall QOL, as measured by
the SF-36 scales and the STAI Trait scale. The one
exception to this was a significantly higher Vitality
score in patients who received the intervention. Table
5 reports the estimated mean scores for each scale for
each time point from longitudinal mixed-effects mod-
els.
Contrary to the results of the ITT analyses and
consistent with our hypothesis, the GSI was impacted
significantly by the intervention, an effect that also
TABLE 3
Quality-of-Life Intent-to-Treat Comparison: Estimated Means from Longitudinal Analyses by Randomization Group
Characteristic
Mean (SE)
P valueRandomized to intervention Randomized to control Contrast
Baseline
SF-36
Physical functioning 67.5 (6.3) 71.4 (4.4) 3.9 (7.7) 0.62
Bodily pain 64.1 (4.3) 55.4 (5.5) 8.7 (7.0) 0.22
General health 65.8 (4.1) 57.7 (4.8) 8.1 (6.3) 0.21
Vitality 47.9 (4.0) 40.0 (4.5) 7.9 (6.0) 0.20
Social functioning 71.5 (4.4) 58.2 (6.1) 13.3 (7.5) 0.09
Mental health 60.0 (4.0) 54.9 (4.2) 5.1 (5.9) 0.39
STAIT 44.2 (2.4) 44.1 (1.4) 0.1 (2.8) 0.99
Two-month follow-up
SF-36
Physical functioning 76.4 (5.9) 78.7 (4.0) 2.3 (7.2) 0.75
Bodily pain 71.9 (5.0) 66.4 (5.5) 5.5 (7.5) 0.46
General health 71.0 (3.9) 53.8 (4.8) 17.1 (6.2) 0.008
Vitality 55.6 (4.3) 42.1 (4.6) 13.5 (6.3) 0.04
Social functioning 85.9 (4.8) 70.1 (5.7) 15.8 (7.4) 0.04
Mental health 72.6 (3.9) 57.0 (4.7) 15.6 (6.1) 0.01
STAIT 39.3 (2.4) 44.4 (2.2) 5.1 (3.3) 0.12
Six-month follow-up
SF-36
Physical functioning 74.5 (5.2) 82.8 (4.4) 8.3 (6.8) 0.23
Bodily pain 70.1 (5.6) 70.2 (4.8) 0.02 (7.3) 0.10
General health 70.2 (4.6) 57.7 (4.8) 12.4 (6.0) 0.05
Vitality 54.6 (4.4) 44.2 (4.3) 10.4 (6.1) 0.10
Social functioning 86.1 (4.7) 79.4 (4.3) 6.6 (6.4) 0.30
Mental health 72.3 (3.5) 61.5 (5.0) 10.8 (6.1) 0.09
STAIT 38.5 (2.2) 45.4 (2.8) 6.9 (3.5) 0.06
a SE: standard error; SF-36: Medical Outcomes Survey-Short Form-36; STAIT: State-Trait Anxiety Inventory (Trait).
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was reflected in the STAI State score and the Anxiety
scale of the BSI, at the 2-month follow-up. In each
occasion, patients who received the intervention had
lower scores, reflective of better emotional well being,
compared with patients who did not receive the inter-
vention. The 2-month differences were observed at
the 6-month follow-up for the Anxiety scale, with dif-
ferences in both the GSI and the STAI State scores
approaching significance (P  0.08 and P  0.05,
respectively). It also is noteworthy that the interven-
tion group scores on the GSI at both 2-month follow-
up and 6-month follow-up were in the normal range,
whereas the scores for the nonintervention group
were  1 standard deviation of the mean, indicating
moderate distress. Table 6 presents the mean scores
with standard errors and the significant differences
between the two groups at each time point.
Comparison of patients who received the inter-
vention with patients those who did not receive the
intervention revealed significant improvements in
Bodily Pain scores (P  0.05) and General Health
scores (P  0.02) at the 2-month follow-up, with con-
tinued differences observed in Vitality scores (P
 0.008). For each scale, scores were higher, reflecting
greater health functioning, for the intervention group.
Vitality scores (P  0.04) continued to be significantly
higher for the intervention group at the 6-month fol-
low-up, with General Health scores (P  0.05) and
Social Functioning scores (P  0.07) approaching sig-
nificance.
DISCUSSION
Increased levels of distress can have an adverse im-
pact on an individual’s ability to make decisions, ad-
here to treatment recommendations, or engage in
posttreatment screening and preventive behav-
iors.32–35 Thus, identifying ways to reduce distress in
individuals with cancer is of great importance. Previ-
ous studies designed to reduce distress in patients
with cancer have reported positive improvements in
distress, coping, and survival.9,19 –22 The unstructured,
lengthy, or group format of these interventions, how-
ever, may make them difficult to incorporate into ex-
isting medical systems. Because few brief, replicable
therapeutic interventions aimed at decreasing distress
and improving QOL have been tested, the current
study was designed to determine whether a struc-
tured, individual intervention could reduce distress
and improve QOL.
The primary objectives of the current study may
be examined from an ITT approach and an EOI ap-
proach, because both methods answer separate yet
equally important questions. The ITT approach exam-
ines the effectiveness of an intervention in changing a
particular behavior or, in this study, reducing distress
and, secondarily, improving QOL. Using this approach
in the current study revealed that the intervention did
not effectively reduce overall emotional distress, al-
though it did reduce anxiety and improve several as-
pects of QOL. At the 2-month and 6-month follow-up
TABLE 4
Distress/Depression/Anxiety Intent-to-Treat Comparison: Estimated Means from Longitudinal Analyses by Randomization Group
Characteristic
Mean (SE)
P valueRandomized to intervention Randomized to control Contrast
Baseline
BSI
Global severity index 65.3 (1.2) 64.9 (1.3) 0.4 (1.8) 0.81
Depression index 64.9 (1.3) 63.6 (1.9) 1.2 (2.3) 0.59
Anxiety index 62.4 (1.6) 62.5 (2.0) 0.04 (2.6) 0.99
STAIS 44.3 (2.2) 46.1 (2.6) 1.8 (3.4) 0.60
Two-month follow-up
BSI
Global severity index 58.1 (1.8) 61.1 (1.9) 3.0 (2.6) 0.25
Depression index 59.5 (1.9) 60.3 (2.2) 0.7 (2.9) 0.80
Anxiety index 54.7 (1.8) 59.3 (2.2) 4.6 (2.9) 0.11
STAIS 37.1 (2.3) 45.6 (2.9) 8.5 (3.7) 0.02
Six-month follow-up
BSI
Global severity index 57.7 (2.3) 61.6 (2.3) 4.0 (3.2) 0.23
Depression index 57.7 (2.4) 61.1 (2.4) 3.4 (3.4) 0.33
Anxiety index 51.6 (2.0) 59.1 (2.2) 7.4 (2.9) 0.02
STAIS 36.1 (2.1) 42.9 (3.5) 6.8 (4.1) 0.10
a SE: standard error; BSI: Brief Symptom Inventory; STAIS: State-Trait Anxiety Inventory (State).
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assessments, anxiety was significantly lower in the
intervention group compared with the standard care
group, suggesting that improvements can be achieved
through a brief, portable, easily administered, manu-
alized CBI. In support of our secondary objectives, an
additional positive outcome was improvement in
QOL, as measured by the General Health, Vitality,
Social Functioning, and Mental Health scales of the
SF-36. Initial benefits (2-month assessment) of the
intervention were most obvious, whereas the 6-month
follow-up analyses revealed that many of the gains
made at the initial assessment were reduced over
time, although the intervention group continued to
report greater levels of General Health compared with
the standard care group.
Several issues arise in response to the observed
findings, including the need to determine why the
intervention was not effective in reducing general dis-
tress. The lack of effectiveness may have been the
result of an inadequate number of sessions or provi-
sion of material in the intervention that did not have a
direct effect on distress. Although it is possible that
four sessions were not sufficient for changing an in-
dividual’s level of distress, other studies have found
improvements after similar numbers of sessions and
even with fewer sessions.18,21 In addition, the material
used in the sessions has been used in prior studies
with demonstrated effectiveness.21,22 Therefore, it is
likely that another issue was responsible for the lack of
findings. An examination of the responses of individ-
uals who were randomized to the intervention re-
vealed that almost half of the intervention group de-
clined to receive the intervention. Because acceptance
of a treatment is an important part of determining
whether a treatment program is effective, this finding
may account for the lack of a significant difference
between groups. In the ITT analysis, patients who
declined to receive the intervention were included
among the patients who received it, a practice, it may
be argued, that reduces the likelihood of finding sig-
nificant differences and does not provide an accurate
description of the ability of the intervention to reduce
distress, despite identifying problems with the accep-
tance of the intervention. Examination of the reasons
TABLE 5
Quality-of-Life Intervention Comparison: Estimated Means from Longitudinal Analyses by Receipt of Intervention
Characteristic
Mean (SE)
P valueReceived intervention Did not receive intervention Contrast
Baseline
SF-36
Physical functioning 72.9 (6.6) 67.8 (4.6) 5.1 (8.0) 0.53
Bodily pain 66.5 (4.1) 57.0 (4.6) 9.5 (6.2) 0.14
General health 65.2 (5.1) 60.4 (4.0) 4.7 (6.5) 0.47
Vitality 54.6 (4.5) 39.6 (3.6) 14.9 (5.8) 0.01
Social functioning 71.2 (5.5) 62.3 (5.0) 8.9 (7.4) 0.24
Mental health 57.9 (5.5) 57.3 (3.5) 0.6 (6.5) 0.93
STAIT 44.6 (3.4) 44.0 (1.4) 0.7 (3.6) 0.85
Two-month follow-up
SF-36
Physical functioning 83.6 (6.1) 74.3 (4.6) 9.3 (7.6) 0.23
Bodily pain 78.7 (5.2) 64.4 (4.7) 14.4 (7.0) 0.05
General health 73.3 (4.8) 57.7 (4.0) 15.6 (6.2) 0.02
Vitality 60.9 (5.2) 43.3 (3.7) 17.6 (6.4) 0.008
Social functioning 85.6 (5.2) 74.8 (4.9) 10.8 (7.1) 0.14
Mental health 72.5 (5.3) 61.6 (3.8) 10.9 (6.5) 0.10
STAIT 39.3 (3.2) 43.0 (1.9) 3.7 (3.7) 0.33
Six-month follow-up
SF-36
Physical functioning 79.3 (5.0) 77.7 (4.8) 1.6 (6.9) 0.82
Bodily pain 75.5 (6.0) 68.8 (4.3) 6.8 (7.4) 0.37
General health 72.0 (4.5) 60.0 (3.9) 12.0 (6.0) 0.05
Vitality 58.7 (5.8) 44.7 (3.4) 14.0 (6.7) 0.04
Social functioning 89.9 (4.1) 78.9 (4.2) 11.0 (5.9) 0.07
Mental health 72.0 (4.8) 64.6 (3.9) 7.4 (6.2) 0.24
STAIT 37.9 (2.9) 43.7 (2.3) 5.7 (3.6) 0.12
a SE: standard error; SF-36: Medical Outcomes Survey-Short Form-36; STAIT: State-Trait Anxiety Inventory (Trait).
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why individuals declined to receive the intervention
included having to travel back to the medical center,
living too far away, and not believing that the inter-
vention was needed. Therefore, it appears that the
reasons for the lack of acceptance were not inherent in
the intervention but in practical issues with transpor-
tation and distance. This finding points to the need to
identify additional intervention strategies that would
overcome these limitations.
The identification of patients who declined to en-
gage in the intervention led us to use a second EOI
analysis to determine the efficacy of the intervention.
In that analysis, the intervention did have the in-
tended effect of reducing distress, with 2-month GSI
scores in the intervention group that were significantly
lower compared with the nonintervention group. Lev-
els of anxiety also were lower in the intervention group
at the 2-month follow-up. The importance of these
results is tempered somewhat by the finding that at
the 6-month follow-up, the differences between
groups in terms of overall distress only approached
significance. Despite the lack of a statistical difference,
the intervention group continued to have BSI scores in
the normal range, whereas the nonintervention group
continued to exceed the level that has been identified
as indicative of moderate distress.7,23,24 In addition,
patients in the intervention group continued to report
improved health-related QOL.
The lack of longer-term improvements in the pa-
tients who received the intervention is not surprising
in light of the fact that patients received only one
session on each topic designed to reduce distress.
Traditional cognitive-behavioral therapy is designed
to produce change in thoughts and behaviors after
repeated presentation of the material and exercises for
patient integration of the strategies learned. For ex-
ample, the problem-solving therapy that was pre-
sented in 1 session in the current study has been
presented and revisited repeatedly over 10 sessions of
therapy.36 This suggests that a longer intervention,
which would provide multiple sessions for patient
learning as well as effective implementation of these
strategies, would result in longer-term change. Be-
cause such an approach may be too intensive for clinic
settings, repeated bolus maintenance sessions pro-
vided on a regular basis may be beneficial in extending
the initial change observed in the current study. Nev-
ertheless, the results from the current study provide
initial support for identifying individuals at increased
distress, providing them with an intervention, and
tracking their progress.
We advocated this approach in a previous report37
and believe that such an approach should be consid-
ered when attempting replication in either melanoma
or other oncology samples. This approach would in-
clude 1) targeting a clinic with a high enough clinical
output that 30% of patients (those likely to be in dis-
tress) would represent enough participants to test an
TABLE 6
Distress/Depression/Anxiety Intervention Comparison: Estimated Means from Longitudinal Analyses by Receipt of Intervention
Characteristic
Mean (SE)
P valueReceived intervention Did not receive intervention Contrast
Baseline
BSI
Global severity index 65.9 (1.8) 64.7 (1.0) 1.2 (2.1) 0.57
Depression index 65.7 (1.9) 63.5 (1.4) 2.2 (2.4) 0.37
Anxiety index 63.7 (2.3) 61.9 (1.5) 1.9 (2.8) 0.50
STAIS 45.8 (3.1) 45.0 (2.0) 0.8 (3.7) 0.83
Two-month follow-up
BSI
Global severity index 55.1 (2.3) 62.1 (1.5) 7.0 (2.8) 0.01
Depression index 56.8 (2.4) 61.7 (1.8) 4.9 (3.0) 0.11
Anxiety index 51.4 (2.5) 59.6 (1.7) 8.2 (3.0) 0.009
STAIS 35.5 (3.1) 43.9 (2.3) 8.3 (3.8) 0.03
Six-month follow-up
BSI
Global severity index 55.4 (2.7) 61.5 (1.9) 6.1 (3.3) 0.083
Depression index 56.3 (2.8) 60.8 (2.1) 4.5 (3.5) 0.20
Anxiety index 49.3 (2.5) 58.2 (1.8) 8.9 (3.0) 0.01
STAIS 34.5 (2.7) 42.1 (2.7) 7.6 (3.8) 0.05
a SE: standard error; BSI: Brief Symptom Inventory; STAIS: State-Trait Anxiety Inventory (State).
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intervention; 2) triaging only those patients most likely
to benefit from the intervention (i.e., moderately-to-
highly distressed patients) to treatment; 3) treating
patients using methods likely to be associated with
minimal disruption of medical clinical operations but
with maximum reliability and power for measuring
change, such as CBIs (e.g., relaxation training, cogni-
tive reframing, information on coping) that have
proven efficacy in patients with cancer and other
health conditions18 –21,38,39; and 4) tracking participant
change using multiple outcome measures (e.g., QOL,
distress, coping, adherence, resource utilization) to
further refine the first 3 steps.
Tracking in the current study revealed that pa-
tients did not complete assessments at all occasions.
In fact, approximately 30% of the sample did not com-
plete 6-month questionnaires. The loss of patients to
follow-up is a limitation in the current study that
resulted in the use of a mixed-effects model analysis to
average patient scores instead of a repeated-measures
analysis of variance. This method was chosen to use
each patient’s response where it occurred and to allow
the inclusion patients in the model with the data they
completed. Despite the loss of data, the drop-out pat-
tern was the same for each group, suggesting that if
recurrences or other disease-related issues were the
reasons for dropping out, then they affected both
groups equally. Nevertheless, the loss of patient data
over time indicates the need for increased attention to
and implementation of mechanisms in future longitu-
dinal studies designed to increase questionnaire com-
pletion.
In conclusion, the current study reports on the
provision of a short-term CBI for reducing distress and
improving QOL in a sample of patients with mela-
noma who had high-to-medium distress. Although in-
creased attention and further research are needed to
develop ways of increasing the acceptance of the in-
tervention, the results provide initial support for its
efficacy in the short term and the ability to maintain
lower levels of distress over a 6-month period. Con-
tinued research using a 4-T approach, as discussed
above, will be important in reducing the distress that
is present in a significant number of patients who are
confronted with new diagnoses of cancer and discus-
sions of its treatments.
REFERENCES
1. Jackson A, Wilkinson C, Ranger M, Pill R, August P. General
practice: can primary prevention or selective screening for
melanoma be more precisely targeted through general prac-
tice? A prospective study to validate a self-administered risk
score. Br Med J. 1998;316:34 –38.
2. Marks R. Epidemiology of melanoma. Clin Exp Dermatol.
2000;25:459 – 463.
3. National Cancer Institute. Surveillance, epidemiology, and
end results [monograph online]. Available from URL: http://
www.seer.cancer.gov [Accessed February 2003]
4. American Cancer Society. Cancer facts and figures, 2002.
Atlanta: American Cancer Society, 2002.
5. Balch CM, Buzaid AC, Seng-Jaw S, et al. Final version of the
American Joint Committee on Cancer staging system for
cutaneous melanoma. J Clin Oncol. 2001;19:3635–3648.
6. Trask PC, Paterson AG, Hayasaka S, Dunn RL, Riba M,
Johnson T. Psychosocial characteristics of individuals with
non-Stage IV melanoma. J Clin Oncol. 2001;19:2844 –2850.
7. Derogatis LP, Morrow GR, Fetting J, et al. The prevalence of
psychiatric disorders among cancer patients. JAMA. 1983;
249:751–757.
8. Sollner W, Zingg-Schir M, Rumpold G, Mairinger G, Fritsch
P. Need for supportive counseling-the professionals’ versus
the patients’ perspective. Psychother Psychosom. 1998;67:
94 –104.
9. Fawzy FI, Fawzy NW, Hyun CS, et al. Malignant melanoma.
Effects of an early structured psychiatric intervention, cop-
ing, and affective state on recurrence and survival 6 years
later. Arch Gen Psychiatry. 1993;50:681– 689.
10. Havlik RJ, Vukasin AP, Ariyan S. The impact of stress on the
clinical presentation of melanoma. Plast Reconstr Surg.
1992;90:57– 64.
11. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk
factor for noncompliance with medical treatment. Arch In-
tern Med. 2000;160:2101–2107.
12. Batel-Copel LM, Kornblith AB, Batel PC, Holland JC. Do
oncologists have an increasing interest in the quality of life
of their patients? A literature review of the last 15 years. Eur
J Cancer. 1997;1:29 –32.
13. Cella DF, Bonomi AE. Measuring quality of life: 1995 update.
Oncology. 1995;9:47– 60.
14. Portenoy RK, Thaler HT, Kornblith AB, et al. Symptom prev-
alence, characteristics and distress in a cancer population.
Qual Life Res. 1994;3:183–189.
15. Schipper H, Clinch J, McMurray M, Levitt M. Measuring the
quality of life of cancer patients: the Functional Living In-
dex-Cancer: development and validation. J Clin Oncol. 1984;
5:472– 473.
16. Brown JE, King MT, Butow PN, Dunn SM, Coates AS. Pat-
terns over time in quality of life, coping and psychological
adjustment in late stage melanoma patients. Qual Life Res.
2000;9:75– 85.
17. Trijsburg RW, van Knippenberg FCE, Rijpma SE. Effects of
psychological treatment on cancer patients: a critical re-
view. Psychosom Med. 1992;54:489 –517.
18. Andersen BL. Biobehavioral outcomes following psycholog-
ical interventions for cancer patients. J Consult Clin Psychol.
2002;70:590 – 610.
19. Alter CL, Fleishman S, Kornblith A, et al. Supportive tele-
phone intervention for patients receiving chemotherapy: a
pilot study. Psychosomatics. 1996;37:425– 431.
20. Donnelly J, Kornblith AB, Fleishman S, et al. A pilot study of
interpersonal psychotherapy by telephone with cancer pa-
tients and their partners. Psychooncology. 2000;9:44 –56.
21. Fawzy FI. Psychosocial interventions for patients with can-
cer: what works and what doesn’t. Eur J Cancer. 1999;35:
1559 –1564.
22. Fawzy FI, Fawzy NW, Arndt LA, Pasnau RO. Critical review
of psychosocial interventions in cancer care. Arch Gen Psy-
chiatry. 1995;52:100 –113.
Cognitive-Behavioral Intervention/Trask et al. 863
23. Derogatis LR. The Brief Symptom Inventory (BSI): adminis-
tration, scoring and procedures. Manual II. Baltimore: Clin-
ical Psychometric Research, Inc., 1992.
24. Derogatis LR, Melisaratos N. The Brief Symptom Inventory:
an introductory report. Psychol Med. 1983;13:595– 605.
25. Boulet J, Boss MW. Reliability and validity of the Brief Symp-
tom Inventory. Psychol Assess. 1991;3:433– 437.
26. Ware JE. SF-36 Health Survey: manual and interpretation
guide. Boston: Health Institute, New England Medical Cen-
ter, 1993.
27. Spielberger CD. Manual for the State-Trait Anxiety Inven-
tory: STAI (Form Y). Palo Alto: Consulting Psychologists
Press, 1983.
28. Spielberger CD, Sydeman SJ. State-Trait Anxiety Inventory
and State-Trait Anger Expression Inventory. In: Maruish
ME, editor. The use of psychological tests for treatment
planning and outcome assessment. Hillsdale, NJ: Lawrence
Erlbaum Associates, 1994:292–321.
29. Verbeke G, Molenberghs G. Linear mixed models in practice: a
SAS-oriented approach. New York: Springer-Verlag, 1997.
30. Laird NM, Ware JH. Random effects models for longitudinal
data. Biometrics. 1982;38:963–974.
31. Laird NM. Missing data in longitudinal studies. Stat Med.
1988;7:305–315.
32. Dermatis H, Lesko LM. Psychological distress in parents
consenting to child’s bone marrow transplantation. Bone
Marrow Transplant. 1990;6:411– 417.
33. Dermatis H, Lesko LM. Psychosocial correlates of physician-
patient communication at time of informed consent for
bone marrow transplantation. Cancer Invest. 1991;9:621–
628.
34. Raghunathan R, Pham MT. All negative moods are not
equal: motivational influences of anxiety and sadness on
decision-making. Organ Behav Hum Decis Process. 1999;79:
56 –77.
35. Glasgow RE, Orleans CT. Adherence to smoking cessation
regimens. In: Gochman DS, editor. Handbook of health
behavior research. Volume 2. Provider determinants. New
York: Plenum Press, 1997:353–377.
36. Nezu AM, Nezu CM, Friedman SH, Faddis S, Houts PS.
Helping cancer patients cope: a problem-solving approach.
Washington: American Psychological Association, 1998.
37. Trask PC, Schwartz SM, Deaner SL, et al. Behavioral medi-
cine: the challenge of integrating psychological and behav-
ioral approaches into primary care. Eff Clin Pract. 2002;5:
75– 83.
38. Andersson G, Stromgren T, Strom L, Lyttkens L. Random-
ized controlled trial of internet-based cognitive behavior
therapy for distress associated with tinnitus. Psychosom
Med. 2002;64:810 – 816.
39. Strom L, Pettersson R, Andersson G. A controlled trial of
self-help treatment of recurrent headache conducted via the
Internet. J Consult Clin Psychol. 2000;68:722–727.
864 CANCER August 15, 2003 / Volume 98 / Number 4
